Global Regulatory Updates on Clinical Trials (October 2025)
Written by: Blaine Van Leuven, MS, MBA, RAC
Executive Director, Regulatory and Strategic Development – CMC
Global regulators remained active in October 2025, issuing new and revised guidance that impacts how drug and biologic trials are designed, conducted, and reported. Caidya’s Regulatory & Strategic Development (RSD) team has included a high-level summary of Guidelines issued by the US FDA, EMA (European Union), NMPA (China), TGA (Australia), Health Canada, and ICH (International Council for Harmonisation) which are important for stakeholders.
FDA (United States)
Final Updates
- Technical Specifications for Submitting Clinical Trial Data Sets for Response Assessments for Treatments of Acute Leukemias (Final, Oct 2025). New technical specs define the response-assessment data elements FDA expects in NDAs/BLAs for acute leukemias, aligning efficacy data submissions across Phases I–IV oncology trials.
Draft Updates
- ICH E20 Adaptive Designs for Clinical Trials (Draft, Step 2b; FDA notice posted in 2025). FDA announced availability of the ICH E20 draft, covering planning, conduct, and reporting for adaptive designs in confirmatory trials; once adopted, it influences US Phase II–III design choices.
European Medicines Agency (EMA)
Final
- Paediatric clinical trials page update noting CTIS information (Updated Oct 1, 2025). EMA refreshed guidance points and signposts for how paediatric trials are registered and reported in CTIS under the EU Clinical Trials Regulation, which affects EU submissions across phases that include children.
Drafts
- Draft concept paper on the development of a reflection paper on the use of external controls for evidence generation in regulatory decision-making
(Public consultation closed Oct 31, 2025).
The Committee for Medicinal Products for Human Use (CHMP) / Methodology Working Party (MWP) intends to develop a reflection paper that will outline general principles for assessing when external controls could be appropriate for regulatory decision making.
The draft concept paper outlines the scope and content of the reflection paper.
NMPA (China)
Final Updates
- No NMPA notices in October 2025 specifically changed drug clinical trial requirements for Phases I–IV on nmpa.gov.cn or its English portal.
Draft Updates
- None located in October 2025 that targeted drug clinical trial phases. (Most October items were device policy explainers or unrelated administrative posts.) nmpa.gov.cn
TGA (Australia)
Final Updates
- No October 2025 updates
Draft Updates
- No updates in October 2025 that would modify Phase I–IV drug/biologic trials.
Health Canada
Final Updates
- Guidance on management of drug submissions and applications (Oct 1, 2025). Broad process guidance updated on Oct 1. It primarily covers submissions management and does not change Division 5 clinical trial rules, but it can impact CTA process logistics. canada.ca
Draft Updates
- None in October 2025 that directly revise Division 5 clinical trial requirements.
International Council for Harmonisation (ICH)
Final Updates
- ICH E6(R3) Module 1 Training “Introduction and Foundational Concepts) now available on the ICH website (08 October 2025) (ICH Official web site : ICH)
Draft Updates
- E20 Adaptive Designs for Clinical Trials (Step 2b, ongoing consultation). Draft guideline addresses prospectively planned adaptations in confirmatory clinical trials with focus on principles for the planning, conduct, analysis and interpretation of clinical trials with an adaptive design.